Physician profile
Thomas J Jackson
NPI 1528262698
$5,300.27
in general payments reported to CMS, 2019-2025
45 companies · $451 in 2025
The $451 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,041 · 2020: $196 · 2022: $1,034 · 2023: $1,104 · 2024: $1,474 · 2025: $451.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,932 · Education: $97.30.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,932.13 |
| Education | $97.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,222.11 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $477.34 | 2019-2025 | |
| Novo Nordisk INC | $377.33 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $330.27 | 2022-2025 | Otezla, Repatha, Evenity |
| Pfizer INC. | $320.64 | 2019-2023 | |
| Astellas Pharma US INC | $228.72 | 2019-2024 | Veozah, Myrbetriq |
| Glaxosmithkline, LLC. | $226.16 | 2022-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Lundbeck LLC | $205.18 | 2022-2025 | Rexulti |
| Lilly USA, LLC | $194.01 | 2019-2025 | Mounjaro, Zepbound, Trulicity |
| Janssen Pharmaceuticals, INC | $140.29 | 2019-2024 | Xarelto |
| Dexcom, INC. | $131.24 | 2022-2024 | Dexcom G6 Transmitter |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $110.86 | 2019-2024 | Xifaxan |
| Allergan, INC. | $104.11 | 2019-2020 | |
| Astrazeneca Pharmaceuticals Lp | $93.78 | 2019-2025 | Breztri, Airsupra |
| Biohaven Pharmaceutical Holding Company Ltd. | $93.10 | 2022 |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Jackson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.